Relationships between atherogenic index of plasma and body mass index with the risk of type 2 diabetes mellitus: insights from CHARLS
- PMID: 40332562
- DOI: 10.1007/s00592-025-02516-0
Relationships between atherogenic index of plasma and body mass index with the risk of type 2 diabetes mellitus: insights from CHARLS
Abstract
Background: The complex relationship between obesity and dyslipidemia in type 2 diabetes mellitus (T2DM) remains an area of interest but is not fully understood. This study aimed to evaluate the intricate links between atherogenic index of plasma (AIP), body mass index (BMI), and T2DM risk.
Methods: Based on data from the China Health and Retirement Longitudinal Study, this analysis comprised 6754 individuals aged 45 and over, free of T2DM in 2011. BMI and AIP were the exposures, with T2DM incidence as the primary focus. Logistic regression models generated odds ratios (ORs), and a thorough decomposition of BMI's impact on T2DM revealed natural indirect and direct effects. The study also examined the complex interactions and combined effects of these two exposures.
Results: By the end of 2018, 972 individuals were diagnosed with T2DM. The AIP played a significant association in the relationship between BMI and T2DM, explaining 21.7% and 18.9% of the association in different BMI ranges. A significant additive effect was observed between BMI and AIP, with a relative excess risk due to interaction of 0.62. BMI ≥ 24.0 kg/m2 and AIP above the median together conferred the highest risk of T2DM, with an OR of 2.31 and a 95% confidence interval (CI) of 1.92-2.79.
Conclusion: Exposure to overweight/obesity or high AIP raises T2DM risk among Chinese ≥ 45 years, AIP partly mediates BMI-T2DM link.
Keywords: Atherogenic index of plasma; Body mass index; CHARLS; Mediating effect; Type 2 diabetes mellitus.
© 2025. Associazione Medici Diabetologi / Association of Diabetologists (AMD), Societa Italiana di Diabetologia / Italian Society of Diabetology (SID).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no potential competing interests. Ethics approval and consent to participate: The studies involving human participants were reviewed and approved by the Ethics Review Committee of Peking University (IRB0000105211, 015). The participants provided their written informed consent to participate in this study. Consent for publication: All authors read and approved the final manuscript.
Similar articles
-
Non-linear associations of atherogenic index of plasma with prediabetes and type 2 diabetes mellitus among Chinese adults aged 45 years and above: a cross-sectional study from CHARLS.Front Endocrinol (Lausanne). 2024 Apr 2;15:1360874. doi: 10.3389/fendo.2024.1360874. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38628590 Free PMC article.
-
Nonlinear association between atherogenic index of plasma and type 2 diabetes mellitus in overweight and obesity patients: evidence from Chinese medical examination data.Cardiovasc Diabetol. 2024 Jun 29;23(1):226. doi: 10.1186/s12933-024-02330-y. Cardiovasc Diabetol. 2024. PMID: 38951808 Free PMC article.
-
Atherogenic index of plasma and obesity-related risk of stroke in middle-aged and older Chinese adults: a national prospective cohort study.Diabetol Metab Syndr. 2024 Oct 8;16(1):245. doi: 10.1186/s13098-024-01481-y. Diabetol Metab Syndr. 2024. PMID: 39380102 Free PMC article.
-
The longitudinal effect of the atherogenic index of plasma on type 2 diabetes in middle-aged and older Chinese.Acta Diabetol. 2022 Feb;59(2):269-279. doi: 10.1007/s00592-021-01801-y. Epub 2021 Oct 14. Acta Diabetol. 2022. PMID: 34648090
-
Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus.Prim Care Diabetes. 2015 Feb;9(1):60-7. doi: 10.1016/j.pcd.2014.03.007. Epub 2014 May 5. Prim Care Diabetes. 2015. PMID: 24810146 Review.
References
-
- Chatterjee S, Khunti K, Davies MJ (2017) Type 2 diabetes. Lancet (Lond, Engl) 389(10085):2239–2251. https://doi.org/10.1016/s0140-6736(17)30058-2 - DOI
-
- (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet (Lond, Engl) 402(10397):203–234. https://doi.org/10.1016/s0140-6736(23)01301-6
-
- Deng W, Zhao L, Chen C et al (2024) National burden and risk factors of diabetes mellitus in China from 1990 to 2021: results from the global burden of disease study 2021. J Diabetes 16(10):e70012. https://doi.org/10.1111/1753-0407.70012 - DOI - PubMed - PMC
-
- Liu J, Liu M, Chai Z et al (2023) Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030. Lancet Region Health Western Pac 33:100700. https://doi.org/10.1016/j.lanwpc.2023.100700 - DOI
-
- Xu Y, Lu J, Li M et al (2024) Diabetes in China part 1: epidemiology and risk factors. Lancet Public Health 9(12):e1089–e1097. https://doi.org/10.1016/s2468-2667(24)00250-0 - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous